Liquid biopsy may guide bladder cancer treatment decisions

NCT ID NCT07581496

Recruiting now Knowledge-focused Sponsor: University Hospital, Basel, Switzerland Source: ClinicalTrials.gov ↗

First seen May 15, 2026 · Last updated May 15, 2026

Summary

This study looks at whether DNA fragments in blood or urine (ctDNA) can help doctors better understand T1G3 bladder cancer, a type that is hard to predict. Researchers will collect samples from 35 adults before and after standard treatments to see if ctDNA levels change and if they relate to cancer progression. The goal is to improve risk assessment and avoid unnecessary treatments, but this is an early exploratory study with no direct treatment benefit for participants.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BLADDER CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••
Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Luzerner Kantonsspital
RECRUITING

Lucerne, Switzerland

Contact Email: •••••@•••••

Contact

Contact Email: •••••@•••••
Universitätsspital Basel
RECRUITING

Basel, Switzerland

Contact

Contact Phone: •••-•••-•••• Email: •••••@•••••

Contact Phone: •••-•••-•••• Email: •••••@•••••

Conditions

Explore the condition pages connected to this study.

BLADDER CANCER